A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN intermediate-risk, stage II-III rectAl cancer

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Institut Jules Bordet

Participant type

Patients

Age range

18-64 years

Gender

Male and Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

29 Mar 2021 → ongoing

Decision date (initial)

2024-08-29

Transition trial

Yes

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Funding sources

Bayer AG

External identifiers

EU CT number

2024-516554-22-00

EudraCT number

2020-000876-40

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Safety, Efficacy

To demonstrate that administering combination treatment with nivolumab plus regorafenib before and after standard, pre-operative SCRT is associated with a promising complete response (CR) rate in subjects with pMMR/MSS tumours.

Secondary objectives 4

1. To assess the safety of the investigational treatment in terms of toxicity during and after completion of pre-operative therapy and intra-/post-operative complications
2. To assess the feasibility of combining regorafenib with nivolumab in the setting of locally-advanced rectal cancer as demonstrated by subject compliance with the investigational strategy, SCRT and surgery (if performed).
3. To assess other efficacy outcome measures including R0 resection rate, pathological tumour regression grade, tumour downstaging/downsizing, disease-free survival, progression-free survival and overall survival.
4. To assess the immune activation induced by the investigational treatment regorafenib with nivolumab as shown by the increase in inflammatory infiltrate in post-treatment tumour tissue samples

Conditions and MedDRA coding

Locally-advanced stage II-III rectal cancer

Study design 1 period

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 18

1. Female or Male
2. Age ≥ 18 years old
3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
4. Histologically or cytologically verified adenocarcinoma of the rectum
5. Tumour with distal border below the peritoneal reflection and within 15 cm from the anal verge
6. Stage cT3/T4a and Nany or cT1-2 and N+ as documented by baseline pelvic MRI
7. Absence of distant metastases as shown by baseline computed tomography (CT) of the thorax-abdomen or CT scan of the thorax and MRI of the abdomen
8. Adequate haematological function as defined by absolute neutrophil count (ANC) ≥1.5 × 109/L, platelet count ≥100 × 109/L, and haemoglobin ≥9 g/dL
9. Adequate hepatic function as defined by a total bilirubin level ≤1.5 × the upper limit of normal (ULN) range (excluding subjects with known Gilbert’s syndrome), and alanine aminotransferase (ALT) levels ≤2.5 × ULN
10. Adequate renal function as defined by an estimated creatinine clearance ≥30 mL/min according to the Cockcroft-Gault or Wright formula
11. Negative serum pregnancy test at screening (up to 7 days before treatment start) for women of childbearing potential
12. treatment start) for women of childbearing potential 12) Women of childbearing potential must agree to use of one highly effective method of contraception prior study entry, during the course of the study and at least 7 months after the last administration of study treatment.
13. Men with childbearing potential partner must agree to use condom during the course of this study and for at least 5 months after the last administration of the study treatment.
14. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
15. Absence of clinical conditions that, in the opinion of the investigator, would contraindicate neoadjuvant therapy and/or surgery
16. Life expectancy of at least 3 months
17. Completion of all necessary screening procedures within 28 days prior to enrolment.
18. Signed Informed Consent form (ICF) obtained prior to any study related procedure.

Exclusion criteria 17

1. Any prior or concurrent surgery, chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for rectal cancer. Concurrent use of hormones for noncancer-related conditions (i.e., insulin for diabetes and hormone replacement therapy) is acceptable.
2. Any contraindication to pelvic irradiation as evaluated by the investigator
3. Prior organ transplantation, including allogeneic stem cell transplantation
4. Clinically significant acute or chronic infections including, among others: - known history of testing positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) - known history of testing positive for hepatitis B virus (HBV) surface antigen or anti-hepatitis C virus (HCV) antibody and confirmatory HCV ribonucleic acid (RNA) test
5. Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent (subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible)
6. Systemic corticosteroids administered as hormone replacement or as immunosuppressants at doses exceeding 10 mg/day of prednisone or equivalent. Other immunosuppressive medications including, but not limited to methotrexate, azathioprine, and TNF-α blockers. Use of immunosuppressive medications for the management of treatmentrelated AEs or in subjects with contrast allergies is acceptable. A temporary period of steroids is allowed for different indications, at the discretion of the investigator (i.e., chronic obstructive pulmonary disease, radiation, nausea, etc.). Administration of steroids through a route known to result in a minimal systemic exposure [topical, intranasal, intro-ocular, or inhalation] is acceptable
7. Known severe hypersensitivity reactions to the investigational treatments, or any excipients or non-investigational medicinal products or concomitant medications
8. Pregnant and/or lactating women
9. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure, uncontrolled arterial hypertension, or serious cardiac arrhythmia requiring medication
10. Prior myocarditis
11. Known history of immune colitis, immune pneumonitis, pulmonary fibrosis or other medical conditions (for example, inflammatory bowel disease, uncontrolled asthma), which, in the opinion of the Investigator, might impair the subject’s tolerance of trial treatment
12. Vaccination within 28 days of the first dose of study treatment and while on trial (except for administration of inactivated vaccines)
13. Other invasive malignancy within 2 years except for non-invasive malignancies such as cervical carcinoma in situ, non-melanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has/have been surgically cured. Anti-neoplastic treatment received in the past for malignancies cured 2 or more years before enrolment are permitted.
14. Any investigational anti-cancer therapy other than the protocol specified therapies.
15. therapies. 15) Strong inhibitors of CYP3A4 activity (e.g. clarithromycin, grapefruit juice, itraconazole, ketoconazole, posaconazole, telithromycin and voriconazole), strong UGT1A9 inhibitors (e.g. mefenamic acid, diflunisal, and niflumic acid), and strong inducers of CYP3A4 (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital and St. John’s wort) from 28 days before study enrolment up to the end of study treatment.
16. Major surgery within 28 days of the first dose of study treatment
17. Presence of gastrointestinal perforation or fistula

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Complete response (CR) rate (including either pathological [pCR] or clinical complete response [cCR]) in subjects with pMMR/MSS tumours

Secondary endpoints 10

1. CR rate in the mMiITT population (including both pMMR/MSS and dMMR/MSI-H tumours)
2. Toxicity
3. Compliance to treatment
4. R0 resection rate
5. Pathological tumour regression grade (pTRG)
6. Local recurrence rate
7. Distant recurrence rate
8. Event-free survival (EFS)
9. Overall survival (OS)
10. CD3 and CD8 T-cells infiltrate increase in post-treatment tumour tissue samples

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut Jules Bordet

Sponsor organisation

Institut Jules Bordet

Address

Mijlenmeersstraat 90

City

Anderlecht

Postcode

1070

Country

Belgium

Scientific contact point

Organisation

Institut Jules Bordet

Contact name

CTSU

Public contact point

Organisation

Institut Jules Bordet

Contact name

CTSU

Locations

1 EU/EEA country · 10 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 40 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

6 submissions — initial application plus substantial / non-substantial modifications